Azacitidine is Used for continued treatment of adults with acute myeloid leukemia who achieved first complete remission following intensive chemotherapy. It was first introduced by Bristol-Myers Squibb Co in its drug Vidaza on May 19, 2004. Other drugs containing Azacitidine are Azacitidine, Onureg. 18 different companies have introduced drugs containing Azacitidine.

Azacitidine Patents

Given below is the list of patents protecting Azacitidine, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Onureg	US8846628	Oral formulations of cytidine analogs and methods of use thereof	Jun 03, 2030	Bristol
Onureg	US11571436	Oral formulations of cytidine analogs and methods of use thereof	May 14, 2029	Bristol
Onureg	US12053482	Oral formulations of cytidine analogs and methods of use thereof	May 14, 2029	Bristol

Add above patents to watchlist

Azacitidine's Family Patents

Full family tree

Azacitidine Generic API Manufacturers

Several generic applications have been filed for Azacitidine. The first generic version for Azacitidine was by Dr Reddys Laboratories Ltd and was approved on Sep 16, 2013. And the latest generic version is by Reliance Life Sciences Pvt Ltd and was approved on May 20, 2025.

Given below is the list of companies who have filed for Azacitidine generic, along with the locations of their manufacturing plants worldwide.